On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of pulmonis cancer, conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes tuberculum cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb detexit societatem applicationem Opdivo subiecisse ad indicia cancri pulmonis curationis ad FDA et ad administrationem pharmaceuticam EU. Scilicet, ambitiosus Squibb Societas naturaliter non solum contenta erit cancro pulmone et melanoma. Re vera, Squibb nunc plura quam 35 studia de solo Opdivo agit, vel in compositione cum aliis medicamentis ad varias tumoris rationes tractandas. Secundum analystas, futurae venditiones Opdivo usque ad 5 miliarda dollariorum usque pervenient.
The cancer immunotherapy research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Retineo Anglica fama:
Bristol-Myers Squibb's ($BMY) standum immuno-o ncologia medicamentum nivolumab, probatum ultimo modo sicut Opdivo, resonans foedum in successu cancri late-scacensi iudicii, venditio elata exspectatione pro curatione pio curante.
In a 272-patiens studium pitting Opdivo contra vexillum cancer occisoris docetaxel, Bristol-Myers demom medicamentum talem altiore superstite supe- rioribus comparatum cum bracchio co ntrol ut primum finem schedulae praecedentem attingat, ducens iudicii notitia mo nitoring commissionis commendare suadeo. studio primo terminabitur. Bristol-Myers nunc aegros in coetus docetaxel invitat ut optet in Opdivo per studium patentem extensionis pittacii.
Curatio Bristol-Myers ordinatur ad liberandos tumores immunes systematis oppugnationis impediendo viam PD-1 vocatam, quae, immoderata relicta, cellulas cancri per naturales defensiones corporis latentes transire permittit. Sicut Merck ($ MRK) similis Keytruda, Opdivo FDA approbavit, anno praeterito tractationem melanomae consecutus est, sed medicamentum Bristol-Myers solum in cancro pulmonis stat, sicut ultimae prosperitatis clinicae primum signum PD-1 inhibitoris charted a. superstes contra morbum, societas dixit.
Opdivo’s particular promise in cellula parva non-pulmonis cancer has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Bristol-Myers applicationes cancri pulmonis in US et Europa pro Opdivo in cancro pulmonis submisit, expectans usum medicamentorum postea hoc anno dilatare.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, caput et collum cancer, glioblastoma, Non-Hodgkin lymphoma and other cancers.
